Arginine supplementation in four patients with X-linked creatine transporter defect
C Fons, A Sempere, A Arias, A López-Sala… - Journal of inherited …, 2008 - Springer
C Fons, A Sempere, A Arias, A López-Sala, P Póo, M Pineda, A Mas, MA Vilaseca…
Journal of inherited metabolic disease, 2008•SpringerBackground Treatment with oral creatine monohydrate has not shown efficacy in patients
with creatine transporter deficiency (CRTR-D). Another therapeutic option proposed is l-
arginine, the substrate for the enzyme l-arginine: glycine amidinotransferase (AGAT). We
evaluate clinical characteristics and cerebral creatine replenishment after l-arginine therapy
in four patients with CRTR-D. Patients and methods Four boys with genetically confirmed
diagnosis of CRTR-D (ages 9–16 years) were supplemented with l-arginine (0.4 g/kg per …
with creatine transporter deficiency (CRTR-D). Another therapeutic option proposed is l-
arginine, the substrate for the enzyme l-arginine: glycine amidinotransferase (AGAT). We
evaluate clinical characteristics and cerebral creatine replenishment after l-arginine therapy
in four patients with CRTR-D. Patients and methods Four boys with genetically confirmed
diagnosis of CRTR-D (ages 9–16 years) were supplemented with l-arginine (0.4 g/kg per …
Background
Treatment with oral creatine monohydrate has not shown efficacy in patients with creatine transporter deficiency (CRTR-D). Another therapeutic option proposed is l-arginine, the substrate for the enzyme l-arginine:glycine amidinotransferase (AGAT). We evaluate clinical characteristics and cerebral creatine replenishment after l-arginine therapy in four patients with CRTR-D.
Patients and methods
Four boys with genetically confirmed diagnosis of CRTR-D (ages 9–16 years) were supplemented with l-arginine (0.4 g/kg per day) for a period of 9 months. Treatment efficacy was evaluated by clinical and neuropsychological assessment and determination of creatine signals by brain proton magnetic resonance spectroscopy (1H-MRS).
Results
Epileptic seizures remained well controlled with antiepileptic drugs in three cases, both before and after l-arginine supplementation. Vineland Adaptive Behaviour Scale did not show any change in communication, daily living skills, socialization or motor skills, and a lack of improvement in brain 1H-MRS follow-up was observed. l-Arginine was discontinued at the end of the observation period.
Conclusions
Nine months of l-arginine supplementation did not show effectiveness in the four patients affected with CRTR-D in this protocol.
Springer